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ABSTRACT
The aims of the present study were, first, to identify signs 
of alveolar bone damage in early stages of experimental 
periodontitis (EP) and, second, to assess its possible prevention 
by treatment with cannabinoid receptor 2 agonist HU 308. 
Experimental periodontitis was induced by injections of 
lipopolysaccharide (LPS) (1mg/ml) in gums surrounding 
maxillary and mandibular first molar, 3 days per week, and 
untreated controls were kept for comparison. Then, a 3-week 
study was conducted including eighteen new rats (six rats per 
group): 1) controls; 2) experimental periodontitis rats; and 
3) experimental periodontitis rats treated daily with HU 308 
(500 ng/ml). After euthanasia, alveolar bone loss was assessed 
by morphometric and histomorphometric techniques, and the 
content of prostaglandin E2 (PGE2) in gingival tissue was 
evaluated by radioimmunoassay. The first signs of alveolar bone 
loss were apparent at 3 weeks of experimental periodontitis 
(ρ<0.05) in the mandibular first molar, but there was no 
detectable change at 1 week, leading us to establish 3 weeks as 
an early stage of experimental periodontitis. Rats subjected to 
3-week experimental periodontitis showed less interradicular 
bone volume, less whole bone perimeter and fewer bone 
formation areas, and higher periodontal space height, bone 
resorption areas, number of osteoclasts and gingival content 
of prostaglandin E2 than controls, while HU 308 prevented, 
at least partially, the deleterious effects (ρ<0.001). We can 
conclude that a 3-week term of lipopolysaccharide-induced 
periodontitis in rats provides a valid model of the early stage 
of the disease, as emerging damage is observed in bone tissue. 
Furthermore, harmful effects at 3 weeks could be prevented 
by local stimulation of cannabinoid receptor 2, before greater 
damage is produced.
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RESUMEN
El objetivo del presente trabajo fue, en primer lugar, identificar 
signos de daño óseo alveolar en estadios tempranos de periodontitis 
experimental y, en segundo lugar, evaluar su posible prevención 
mediante el tratamiento con el agonista del receptor cannabinoide 
2, HU 308. La periodontitis experimental fue inducida por 
inyecciones de lipopolisacárido (1mg/ml) en la encía circundante 
al primer molar maxilar y mandibular, 3 días por semana, en tanto 
que controles no tratados fueron mantenidos para la comparación. 
Posteriormente, un estudio de 3 semanas con dieciocho nuevas 
ratas (seis por grupo) fue desarrollado: 1) controles; 2) ratas 
con periodontitis experimental, y 3) ratas con periodontitis 
experimental tratadas diariamente con HU 308 (500ng/ml). 
Luego de la euthanasia, la pérdida ósea alveolar fue evaluada 
por técnicas morfométricas e histomorfométricas, y el contenido 
de prostaglandina E2 en el tejido gingival fue determinado por 
radioinmunoensayo. Los primeros signos de pérdida ósea alveolar 
fueron evidentes a las 3 semanas de inducción de periodontitis 
experimental (ρ<0.05) en el primer molar mandibular, mientras 
que no hubo cambios detectables luego de 1 semana de inducción, 
hecho que nos condujo a establecer a las 3 semanas como 
un estadio temprano de periodontitis experimental, Las ratas 
sometidas a perdiodontitis experimental de 3 semanas mostraron 
menor volumen óseo interradicular, menor perímetro óseo y menos 
áreas de formación ósea, y mayor altura del espacio periodontal, 
más áreas de reabsorción ósea, mayor número de osteoclastos y 
mayor contenido gingival de prostaglandina E2, en comparación 
a los controles, mientras que el tratamiento con HU 308 previno, 
al menos parcialmente, los efectos deletéreos (ρ<0.001). Podemos 
concluir que el término de 3 semanas de periodontitis inducida 
por lipopolisacárido es un modelo válido de estadio inicial de la 
enfermedad experimental, dado que se evidencia daño emergente 
en el tejido óseo. Asimismo, los efectos deletéreos de 3 semanas 
podrían ser prevenidos por la estimulación local del receptor 
cannabinoide 2, antes que un daño mayor sea producido. 
Palabras clave: periodontitis, cannabinoides, pérdida ósea 
alveolar, prostaglandina E2. 
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INTRODUCTION
Initial stages of periodontal diseases include 
gingivitis and incipient chronic periodontitis. 
Gingivitis is defined as an inflammation of the 
gingival tissue, while periodontitis involves the loss 
of attachment of periodontal tissues from the tooth 
and the loss of alveolar bone. Gingivitis is reversible, 
whereas regeneration after the destruction caused 
by periodontitis is not predictably achievable in 
humans1. Even though most periodontal diseases 
are known to occur in susceptible subjects, their 
onset also depends on colonization by bacteria and 
presence of bacterial products2. Lipopolysaccharide 
(LPS), a toxin produced by gram-negative 
microorganisms, can cause an inflammatory 
process, with the consequent damage in the tooth-
insertion tissues3. In the host tissues, LPS stimulates 
phagocytes to increase the production of cytokines 
such as TNFα, IL-1β, IL-6, IL-10, IL-12 and IL-154. 
Those mediators are responsible for a large number 
of cellular events, including the synthesis of PGE2
5, 
a potent stimulator of bone resorption associated 
with loss of periodontal attachment tissues6. 
Additionally, in animals with periodontitis, PGE2 
has been found to increase in the submandibular 
gland, where it seems to function as an inhibitor 
of salivary secretion7. Thus, although colonization 
by pathogenic microbes is the primary origin of 
damage in periodontal diseases, the host immune-
inflammatory response plays a critical role in the 
development of tissue injury resulting in the loss of 
connective tissue and alveolar bone8.
The cellular and humoral response deployed in 
bacterial processes involves the endocannabinoid 
system (ECS)9,10, which is an intercellular 
communication network that includes receptors, 
endogenous ligands and a series of enzymes 
responsible for ligand synthesis and breakdown. 
Cannabinoid receptors type 1 (CB1r) and type 2 
(CB2r) are the main specific cannabinoid receptors, 
whereas transient receptor potential vanilloid type 1 
is the most throughly studied unspecific receptor11. 
According to the classical concept and even though 
it has been submitted to revisions, CB1 is highly 
expressed in the central nervous system and to a 
lesser extent, in peripheral tissues. Conversely, CB2 
is expressed mainly in peripheral tissues and cells 
such as monocytes, macrophages, lymphocytes 
and bone cells12. However, the stimulation of 
ECS has been associated with anti-inflammatory 
effects through both CB113,14 and CB215 receptors. 
In previous studies, we have shown that in a six-
week LPS-induced periodontitis model in rats, daily 
application of a CB2r synthetic agonist, HU 308, 
attenuated alveolar bone loss and reduced the level 
of inflammatory mediators in gums16.
The aims of this study were, firstly, to identify early 
alveolar bone damage in periodontal disease in 
order to establish initial stages of the disease in an 
experimental model, and secondly, to evaluate the 
effects of the treatment with a CB2 receptor agonist, 
HU 308, on the oral health of rats submitted to early 
periodontitis, and compare these effects with those 
found in the pattern of long-term illness.
MATERIALS AND METHODS
Animals
Adult male Wistar rats (350 g) from the authors’ 
own colony were kept in group cages in an animal 
room with a 12-hour light photoperiod (0700 to 
1900), room temperature maintained at 22°C to 
25°C, and free access to rat chow and tap water. The 
experimental procedures performed were approved 
by the Animal Care Committee of the Dental 
School of the University of Buenos Aires, Buenos 
Aires, Argentina and carried out in accordance with 
guidelines of the National Institutes of Health.
Time range studies
Since our previous studies had been based on a 
six-week lipopolysaccharide-induced periodontitis 
model, we intended to achieve a model of periodontitis 
with emerging damage. To this end, we conducted 
a first experiment based on temporal studies of 
lipopolysaccharide-periodontitis induction at 1, 3 
and 6 weeks. For each term of induction, twelve rats 
were divided into two groups, each group containing 
six rats: 1) control rats, and 2) rats submitted to 
experimental periodontitis. Periodontitis was 
induced by injecting 20 µl of lipopolysaccharide (1 
mg/ml) from Escherichia coli into the vestibular and 
lingual gingiva of the maxillary and mandibular first 
molars and into the interdental space between the 
first and second maxillary and mandibular molars 
(60 µl of lipopolysaccharide per tooth and 240 µl 
per rat at each time of injection). Gingival injections 
were all performed using a 13-mm 27-gauge 
microfine insulin syringe. Control rats received no 
injection during the experiments.
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CB2 receptor studies
In a second experiment, eighteen rats were 
distributed into three groups of six rats per group: 
1) control rats; 2) rats submitted to EP; and 3) rats 
submitted to EP and treated with HU 308, an agonist 
of CB2r. Periodontitis was induced as described for 
the preliminary studies, while control rats received 
no injection during the experiment. This protocol of 
injections was executed for a period of 3 weeks on 
days 1, 3, and 5 of each week, based on a previously 
described method14,17. Gingival injections were 
applied using a 13-mm 27-gauge microfine insulin 
syringe.
Topical treatment with a CB2 receptor agonist
HU 308 ([(1R,2R,5R)-2-[2,6-dimethoxy-4-(2- 
methyloctan-2-yl) phenyl]-7,7-dimethyl-4-bicyclo 
[3.1.1] hept-3-enyl] methanol) was prepared by 
dissolving the powdered drug in 100% ethanol and 
diluting it in saline, containing approximately 1% 
ethanol, to obtain a final concentration of 500 ng/ml 
with which to treat animals.
The volume of each topical application was 200 
µl per tooth, resulting in 800 µl per animal when 
treatment was performed. As mentioned above, 
the second experiment consisted of a 3-week study 
in which group 3 animals received a daily topical 
application of HU 308 at sites of LPS during the 
3 weeks of the experiment. The optimal dose 
of HU 308 was based on previous reports using 
anandamide, but mainly using methanandamide, a 
selective synthetic agonist of CB1 receptor14,18, on 
oral tissues in vivo concomitantly with the dose 
response curves in these preliminary studies.
Macroscopic examination of periodontal bone 
loss: distance and width methods
Immediately after euthanasia of the rats, 
hemimandibles were resected, defleshed, and 
stained with 1% aqueous methylene blue to 
delineate the cementoenamel junction (CEJ) and 
the alveolar crest (AC)19. A stereomicroscope and a 
digital calliper were used to measure three buccal 
and three lingual/palatal distances (mesial, central, 
and distal), from the CEJ to the AC14. The sum of the 
three distances on each side of molars was used as a 
measure of alveolar bone loss (ABL) in millimetres. 
Thus, ABL was assessed on the buccal side, palatal/
lingual side and also as whole tooth of the first upper 
and lower molars. Mandibular alveolar process 
width was measured in the mandibular first molar 
area. Distance between a point located at the central 
root level of the buccal surface and another equally 
located on the lingual surface was measured in the 
mandibles in millimetres using a digital calliper. 
This examination was performed for all the groups 
in the first and second experiments.
Histological analysis
Hemimandibles on the opposite side to those used 
for macroscopic examinations were fixed in formalin 
buffer. After 3 days, they were decalcified in 10% 
EDTA pH 7 for 45 days. Then hemimandibles 
were dehydrated with ethyl alcohol and clarified 
with xylene. Finally, the sector containing the 
first molar of each decalcified hemimandible was 
embedded in paraffin at 56°C to 58°C. Under the 
stereomicroscope, sections oriented mesial-distally 
of each mandibular first molar were cut from the 
paraffin blocks using a microtome. Sections 5 μm 
thick were stained with haematoxylin and eosin 
(H&E), and histomorphometric evaluation was 
performed on digitized microphotographs using 
imaging software. Interradicular bone loss was 
evaluated by measuring the periodontal space 
height, plotting 10 equidistant lines between the 
alveolar crest and the cementum of the furcation 
zone. The length of the lines was measured and the 
mean value was calculated. Additionally, ABL was 
assessed by the following parameter: bone volume 
(B.Ar)/total volume (T.Ar) (%) = fraction of TV 
corresponding to bone tissue. T.Ar was taken as bone 
tissue plus bone marrow and periodontal ligament20. 
The remaining histomorphometric parameters were 
evaluated in the bone of the interdental septum 
located between the first and second lower molars. 
These parameters were: whole perimeter of the 
interdental septum, in μm; bone formation areas, 
in % as Ob.S/BS (osteoblast surface related to total 
bone surface); bone resorption areas, in % as ES/
BS (eroded surface related to total bone surface), 
and number of osteoclasts21,22, as N.Oc/mm, in the 
cervical third of the mentioned septum. Histological 




To determine PGE2 content, gingival tissue 
surrounding first molar was homogenized in 500 
ml absolute ethanol and after centrifugation, 
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supernatants were dried in a centrifugal vacuum 
concentrator at room temperature. Residues were 
then resuspended with buffer, and antiserum was 
used as described in Mohn et al.23. Sensitivity of the 
assay was 12.5 pg per tube. The cross-reactivity of 
PGE2 and PGE1 was 100%, but the cross-reactivity 
of other prostaglandins was 0.1%. The intra- and 
inter-assay coefficients of variation for PGE2 were 
8.2% and 12.0%, respectively. The results were 
expressed in picograms of PGE per milligram of 
wet weight, since the protocol of PGE extraction 
from the tissue includes homogenization in ethanol, 
which interferes with protein determination. This 
evaluation was performed for all the groups in the 
first and second experiments.
Statistical analysis
Data were expressed as mean ± standard error 
of the mean. Results were evaluated by one-way 
analysis of variance followed by the Tukey multiple 
comparisons test for unequal replicates. Only the 
number of osteoclasts was analysed using the 
Kruskal-Wallis nonparametric test. All analyses 
were conducted with Prism software and differences 




• Alveolar bone loss: distance and width methods
After 1 week of LPS injections, ABL measured by 
the distance method did not differ between control 
and LPS groups in either upper or lower first molars 
(Table 1). However, a significant alveolar bone loss 
was noticeable after 3 weeks of LPS induction, 
especially when whole teeth where assessed (Table 
2). Furthermore, the differences described were 
stronger after 6 weeks of LPS induction, when both 
sides of upper and lower first molars as well as the 
whole tooth showed an increase in alveolar bone 
loss in LPS compared to control group (Table 3).
ABL measured by the width method in the mandible 
did not reveal changes between control and EP group 
after 1 and 3 weeks of procedure. In contrast, the 
width of the lower alveolar process was significantly 
lower in the LPS than in control rats after 6 weeks of 
induction (Table 3).
• Radioimmunoassay of prostaglandin E2
PGE2 content was evaluated as a marker of 
inflammatory response in gingival tissue surrounding 
the first molar. PGE2 content measured by RIA was 
markedly higher in gingival tissue after 1, 3 and 6 
weeks of LPS injections in comparison to the control 
group. Results for 1, 3 and 6 weeks are shown at the 
bottom of Tables 1, 2 and 3, respectively.
CB2 receptor stimulation in early stage-
experimental periodontitis rats - Three-week 
studies
• Alveolar bone loss: distance and width methods
In early stage-experimental periodontitis rats, 
alveolar bone loss measured through the distance 
method did not show major changes among 
groups in the first upper molar when buccal and 
palatal sides were analysed separately. In contrast, 
the early-stage experimental periodontitis group 
experienced higher alveolar bone loss than control 
group at the lingual side of the first lower molar, 
Table 1. Macroscopic evaluation of alveolar bone loss through distance and width methods, and gingival 
PGE2 content measurement after one week of LPS applications.
Macroscopic ABL (mm) Control LPS
Distance
First upper molar
Buccal 2.38 ± 0.60 2.54 ± 0.56 
Palatal 2.83 ± 0.78 2.80 ± 0.53
Whole tooth 5.21 ± 1.15 5.33 ± 1.03
First lower molar
Buccal 2.45 ± 0.19 2.57 ± 0.45
Lingual 3.56 ± 0.34 3.70 ± 0.50
Whole tooth 6.01 ± 0.46 6.27 ± 0.58
Width First lower molar 2.62 ± 0.04 2.53 ± 0.02
Gingival PGE2 (pg/mg tissue) 87.30 ± 12.99 154.79 ± 21.74
*
*ρ<0.05 vs. control. ABL: alveolar bone loss. PGE2: prostaglandin E2. LPS: lipopolysaccharide.
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whereas this increase was significantly prevented 
in HU 308-treated group (Table 4). The differences 
mentioned for the lingual side were not detectable 
on the buccal side of the mandibles, except for the 
difference between the control and LPS groups. In 
turn, when the whole tooth was evaluated, both upper 
and lower first molars evidenced the preventive effect 
of HU 308 treatment on alveolar bone loss, increased 
by lipopolysaccharide. In the same 3-week study, 
alveolar bone loss measured by the width method 
did not exhibit significant differences among control, 
early stage-experimental periodontitis and HU 308 
early-stage experimental periodontitis groups in the 
lower first molar (Table 4). 
• Histological analysis
In the analysis of the interradicular bone of the 
first lower molar, the early-stage experimental 
periodontitis and HU 308 early-stage experimental 
periodontitis groups exhibited an increase in the 
periodontal space compared to the control group, 
but did not differ significantly from each other 
after the 3 week-treatment (Fig. 1A and B). On the 
other hand, the evaluation of the alveolar bone area, 
represented as B.Ar/T.Ar (%), revealed that early-
stage experimental periodontitis rats had a lower 
value than control rats, while that reduction was 
prevented, at least partially, by the HU 308 treatment 
(Fig. 1C). 
In the analysis of the interdental septum bone, 
the early-stage experimental periodontitis group 
revealed lower whole perimeter of the interdental 
septum, less bone formation areas, more bone 
resorption areas and higher quantity of osteoclasts 
than the control group. However, HU 308 treatment 
reversed all altered records, showing longer 
perimeter of whole septum, more formation areas, 
fewer resorption areas and fewer osteoclasts than 
the early stage-experimental periodontitis group 
(Fig. 2).
• Radioimmunoassay of prostaglandin E2
Although early-stage experimental periodontitis 
caused a remarkable increase in prostaglandin E2 
Table 2. Macroscopic evaluation of alveolar bone loss through distance and width methods, and gingival 
PGE2 content measurement after three weeks of LPS applications.
Macroscopic ABL (mm) Control LPS
Distance
First upper molar
Buccal 2.70 ± 0.39 3.38 ± 0.64
Palatal 3.00 ± 0.45 3.57 ± 0.71
Whole tooth 5.70 ± 0.60 6.96 ± 1.12 *
First lower molar
Buccal 2.75 ± 0.36 3.75 ± 0.37 *
Lingual 4.37 ± 0.39 4.84 ± 0.39 *
Whole tooth 7.12 ± 0.53 8.58 ± 0.62 *
Width First lower molar 2.65 ± 0.03 2.53 ± 0.06
Gingival PGE2 (pg/mg tissue) 58.97 ± 6.29 124.3 ± 26.13 
*
*ρ<0.05 vs. control. ABL: alveolar bone loss. PGE2: prostaglandin E2. LPS: lipopolysaccharide
Table 3. Macroscopic evaluation of alveolar bone loss through distance and width methods, and gingival 
PGE2 content measurement after six weeks of LPS applications.
Macroscopic ABL (mm) Control LPS
Distance
First upper molar
Buccal 2.78 ± 0.63 4.25 ± 0.65 **
Palatal 3.26 ± 0.27 4.30 ± 0.24 ***
Whole tooth 6.04 ± 0.28 8.56 ± 0.39 ***
First lower molar
Buccal 2.83 ± 0.47 3.85 ± 0.71 *
Lingual 4.08 ± 0.32 5.72 ± 0.58 ***
Whole tooth 7.09 ± 0.30 9.30 ± 0.26 ***
Width First lower molar 2.65 ± 0.03 2.43 ± 0.03 **
Gingival PGE2 (pg/mg tissue) 148.70 ± 3.14 218.00 ± 23.60 
*
*ρ<0.05, **ρ<0.01 and ***ρ<0.001 vs. control. ABL: alveolar bone loss. PGE2: prostaglandin E2. LPS: lipopolysaccharide.
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in comparison to controls, no significant difference 
was found between early-stage experimental 
periodontitis and HU 308-treated groups (Fig. 3). 
However, after the 3-week study period, a downward 
trend can be detected in the CB2r-agonist group with 
respect to early-stage experimental periodontitis.
DISCUSSION
Being one of the most prevalent disorders of the 
oral cavity, periodontal disease has been extensively 
studied in laboratory animals. To this end, endotoxin 
LPS-induced periodontitis has been a method which 
aimed to achieve a more physiological process of 
the spontaneous disease than traumatic methods24,25. 
The traumatic model consists of placing a ligature 
around molars and maintaining it, usually for two 
weeks, which produces a traumatic effect and 
facilitates dental plaque accumulation26. In the LPS-
induced model, toxin reaches periodontal tissues and 
no traumatic effect is generated other than the needle 
Table 4. Macroscopic evaluation of alveolar bone loss measured by the distance method in the first up-
per (A) and lower (B) molar, for control, LPS and LPS+HU 308 groups.
Macroscopic ABL (mm) Control LPS LPS + HU 308
Distance
First upper molar
Buccal 1.25 ± 0.16 1.51 ± 0.13 1.28 ± 0.16
Palatal 1.27 ± 0.16 1.51 ± 0.22 1.22 ± 0.20
Whole tooth 2.52 ± 0.09 3.02 ± 0.13* 2.50 ± 0.11#
First lower molar
Buccal 1.08 ± 0.15 1.36 ± 0.20* 1.25 ± 0.19
Lingual 2.66 ± 0.21 3.70 ± 0.42*** 3.27 ± 0.32 *#
Whole tooth 3.74 ± 0.10 5.22 ± 0.14** 4.52 ± 0.19 **#
Width First lower molar 2.40 ± 0.04 2.34 ± 0.03 2.43 ± 0.04
ABL of buccal and palatal/lingual sides and whole tooth are shown for the first upper and lower molars. The width of the first lower molar is pre-
sented as a complementary evaluation.
 *ρ<0.05, **ρ<0.01 and ***ρ<0.001 vs. control; #ρ<0.05 vs. LPS. ABL: alveolar bone loss. LPS: lipopolysaccharide. HU 308: synthetic agonist of the 
cannabinoid receptor 2.
Fig. 1. A) Photomicrographs (H&E stain; original magnification x40) showing histologic features of the mandibular first molar 
interradicular area of rats subjected to different experimental conditions (control, LPS and LPS+HU 308). B) Periodontal space 
height evaluation. C) Interradicular bone measured as B.Ar/T.Ar (%). Results are presented as mean ± SEM. *ρ<0.05, **ρ<0.01 
and ***ρ<0.001 vs. control; #ρ<0.05 vs. LPS.
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injection. However, scientific literature has not 
reached a consensus with regard to the characteristics 
of this model or to the terms used for the induction. 
Indeed, different authors have run trials lasting 1 
to 10 weeks24,25,27-30. Moreover, in previous studies 
we have demonstrated that LPS injections in first 
molar gums for six weeks produce a set of chemical 
and anatomical changes in periodontal tissues14,16,31. 
At this time, the increase in alveolar bone loss and 
inflammatory mediators such as TNFα, PGE2 and 
nitric oxide (NO) in gingival tissues indicate that 
EP has been established. Therefore, in the current 
study, we firstly focused on evaluating conditions 
of periodontal disease at several periods of time in 
order to clarify the emergence and severity of the 
damage at earlier terms than six weeks. 
Fig. 2. A) Photomicrographs (H&E stain; original magnification x100) showing histologic features of the interdental septum bone 
located between the first and the second lower molars of rats subjected to different experimental conditions (control, LPS and 
LPS+HU 308). B) Whole perimeter of interdental septum bone expressed in μm. C) Bone formation surfaces expressed in % as 
osteoblast surface/total bone surface (Ob.S/BS). D) Bone resorption surfaces expressed in % as eroded surface/total bone surface 
(ES/BS). E) Number of osteoclasts expressed as N.Oc/mm. Results are presented as mean ± SEM. *ρ<0.05 and ***ρ<0.001 vs. con-
trol; #ρ<0.05 and ###ρ<0.001 vs. LPS.
Fig. 3. Content of prostaglandin E2 in gingival tissue: the effect 
of LPS and the application of HU 308. Results are presented as 
mean ± SEM. *ρ<0.05 vs. control.
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We found that no alveolar bone loss was induced 
by LPS injections after one week of the treatment, 
whereas after three weeks, the alveolar bone loss 
by the distance method was significantly higher in 
the LPS-injected group than in the control group. 
Furthermore, the difference between groups was 
even more pronounced after six weeks, when 
the alveolar bone loss was also evident from 
the diminished width. Regarding PGE2 gingival 
content, results showed variability in control 
values among different times assessed in separate 
experiments, which could be associated with the 
high volatility and complicated biology of PGE2, 
in part due to the high number of PGE2 synthesizer 
cells and their variable response to the presence of 
antigens32. Therefore, it is justified to analyse the 
results of each experiment separately. Despite these 
almost inevitable discrepancies, our results showed 
that gingival PGE2 content was significantly higher 
in LPS-induced periodontitis than in control rats at 
each assessed time.
Overall, these findings suggest that in early stages of 
LPS induction, even when alveolar bone damage is 
not clearly marked, gingival tissue expresses some 
sign of inflammation, a stage which could be related 
to gingivitis in human populations33. In addition, 
the first signs of alveolar bone loss at three weeks 
suggest that 3 weeks, or sometime between 1 and 
3 weeks of LPS induction could be defined as the 
beginning of periodontitis in rats, though further 
studies are needed. 
Since initial signs of alveolar bone loss were 
identified after three weeks, we subsequently 
assessed the effects of the HU 308 treatment at 
this time and considered it as an early stage of 
experimental periodontitis. 
At 3-weeks, alveolar bone loss by the distance 
method increased on certain sides by LPS, was 
prevented in HU 308-treated rats. Some differences 
regarding control and LPS values between this 
study and the 3-week term assessed in the study 
time range might be caused by logical variability 
between experiments or due to random factors. In 
any case, distinct alveolar bone damage between 
control and LPS groups was also noticeable in this 
3-week experiment, where even in group treated 
with HU 308, a mitigating effect emerged. In the 
histological analysis, the preventive effect of HU 
308 on bone resorption was confirmed in the bone 
volume evaluation, even though a statistically non-
significant tendency in the same direction could also 
be observed in the periodontal space evaluation. 
These results are consistent with those we found in 
the 6-week treatment, where these initial tendencies 
appeared to be strengthened. In fact, after six weeks, 
LPS-induced damage was clearer on both sides of 
the first upper and lower molars, while the HU 308 
treatment efficiently attenuated it16. Furthermore, 
another study using in vitro human periodontal 
ligament cells demonstrated that LPS increases the 
concentration of IL-1b, IL-6, TNF-a, and RANKL, 
while HU 308 attenuates these parameters, 
normalizing bone metabolism34. On the other hand, 
histomorphometric measures on the interdental 
septum, such as perimeter of bone septum, bone 
formation areas, bone resorption areas and number 
of osteoclasts, lead to a scenario characterized by 
bone resorption in the LPS group and bone formation 
or resorption prevention in the HU 308-treated 
group. In this respect, in a recent study, Kamali et 
al. demonstrated the osteogenic effects of a scaffold 
based on cannabindiol, a natural cannabinoid, on 
bone defects in rats, employing histomorphometric 
measurements, among other techniques35. 
PGE2 content evaluation in the gingival tissue 
showed a higher value in LPS-induced group with 
respect to controls, in agreement with the time 
range studies results. However, this increase was 
not significantly modified by the HU 308 treatment 
at three weeks, although a downward trend was 
evidenced. This result suggests that in a stage of 
emerging damage, HU 308 could start to show an 
incipient preventive effect, which is stronger and 
statistically significant at six weeks of induction20. 
Similarly, in our previous six-week study, other 
inflammatory mediators such as TNFα and NO, 
which were increased in gums by LPS-induced 
periodontitis, also showed the reducing effect of 
the HU 308 treatment. Thus, attenuation of PGE2 in 
gingival tissue reveals the therapeutic potential of 
the CB2r stimulation, providing a potential way to 
reduce inflammatory and immune responses as well 
as to prevent bone resorption, probably through the 
regulation of osteoblast and osteoclast activity36.
In conclusion, a 3-week term of LPS-induced 
periodontitis is a valid model of the early stage of 
the disease, since emerging damage is expressed 
in bone tissue, although it is not as clear as in a 
6-week term. Additionally, we demonstrated herein 
that 3-week harmful effects could be prevented by 
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local stimulation of CB2r with HU 308. Current 
outcomes shortly after the beginning of LPS-
induced periodontitis also support the importance 
of initiating interventions in early stages of the 
pathology, before greater damage is produced, 
thereby preventing irreversible alterations of 
periodontal health in humans.
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